After-Hours Alert: Why iBio Stock Is Plunging

IBio Inc IBIO shares are trading lower in Tuesday's after-hours session after the company reported preliminary results and announced a 1-for-25 reverse split. iBio also said it will not proceed with an IND submission for its COVID-19 vaccine candidate.

iBio expects full-year 2022 revenues of approximately $2.4 million, representing an increase of 1% year-over-year. iBio expects to report a net loss of $50.3 million for the year.

IBio said it ended the quarter with $39.5 million in cash and equivalents. 

"With an expanded portfolio and increasing technical, regulatory, and market challenges for COVID-19 vaccine development, we have decided not to proceed with an IND submission for IBIO-202, our multi-variant COVID-19 vaccine candidate. We also continue to review options to extend our cash runway," said Tom Isett, chairman and CEO of iBio.

iBio also announced that its board approved a 1-for-25 reverse stock split, which will become effective on Oct. 7. iBio shares will begin trading on a post-reverse split basis on Oct. 10.

IBIO Price Action: iBio has a 52-week high of 66 cents and a 52-week low of 22 cents.

The stock was down 33.6% in after hours at 21 cents at time of publication, according to Benzinga Pro.

Photo: Markus Spiske from Pixabay.

Posted In: NewsAfter-Hours CenterMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...